Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer s Disease itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
AUSTIN, Texas, Sept. 06, 2023 Cassava Sciences, Inc. , a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present.
Cassava Sciences (SAVA) Reports Q2 EPS of ($0 63), Provides Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Simufilam Slowed Cognitive Decline by 38% Versus Placebo Over 6 months in Patients with Mild-to-Moderate Alzheimer’s Disease.Drug Effects Favored Mild.